S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
NASDAQ:STAA

STAAR Surgical - STAA Stock Forecast, Price & News

$87.72
+3.21 (+3.80%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$84.72
$90.12
50-Day Range
$62.10
$87.72
52-Week Range
$49.03
$163.08
Volume
429,452 shs
Average Volume
471,590 shs
Market Capitalization
$4.19 billion
P/E Ratio
151.24
Dividend Yield
N/A
Price Target
$92.00

STAAR Surgical MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
4.9% Upside
$92.00 Price Target
Short Interest
Healthy
6.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.78mentions of STAAR Surgical in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2.01 M Sold Last Quarter
Proj. Earnings Growth
72.31%
From $0.65 to $1.12 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

513th out of 1,293 stocks

Ophthalmic Goods Industry

6th out of 7 stocks

STAA stock logo

About STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

STAAR Surgical Price Performance

STAA opened at $87.72 on Tuesday. The firm has a fifty day moving average price of $73.35 and a 200 day moving average price of $70.00. STAAR Surgical has a 1 year low of $49.03 and a 1 year high of $163.08. The stock has a market cap of $4.19 billion, a P/E ratio of 151.24 and a beta of 1.09.

Analysts Set New Price Targets

STAA has been the topic of a number of research reports. Canaccord Genuity Group raised their target price on shares of STAAR Surgical from $81.00 to $89.00 and gave the company a "buy" rating in a research report on Tuesday, April 26th. Canaccord Genuity Group lifted their price objective on shares of STAAR Surgical from $81.00 to $89.00 and gave the stock a "buy" rating in a research report on Tuesday, April 26th. BTIG Research reaffirmed a "buy" rating and issued a $98.00 price objective on shares of STAAR Surgical in a research report on Saturday, April 23rd. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $87.00 price objective on shares of STAAR Surgical in a research report on Tuesday, May 3rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $92.00.

Insider Buying and Selling

In other news, CEO Caren L. Mason sold 35,000 shares of the company's stock in a transaction on Thursday, May 19th. The shares were sold at an average price of $57.49, for a total transaction of $2,012,150.00. Following the completion of the sale, the chief executive officer now owns 83,645 shares of the company's stock, valued at $4,808,751.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.60% of the stock is owned by insiders.

Receive STAA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STAAR Surgical and its competitors with MarketBeat's FREE daily newsletter.

STAA Stock News Headlines

STAAR Surgical Company News
Should You Buy Stocks When the Market Crashes?
STAAR Surgical Tops Q1 EPS by 11c
STAAR Surgical Q1 2022 Earnings Preview
See More Headlines
Receive STAA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STAAR Surgical and its competitors with MarketBeat's FREE daily newsletter.

STAA Company Calendar

Last Earnings
11/03/2021
Today
8/09/2022
Next Earnings (Confirmed)
8/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Ophthalmic goods
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:STAA
CUSIP
85231230
Employees
692
Year Founded
1982

Price Target and Rating

Average Stock Price Forecast
$92.00
High Stock Price Forecast
$98.00
Low Stock Price Forecast
$87.00
Forecasted Upside/Downside
+4.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$24.50 million
Pretax Margin
15.06%

Debt

Sales & Book Value

Annual Sales
$230.47 million
Cash Flow
$0.70 per share
Book Value
$5.43 per share

Miscellaneous

Free Float
46,568,000
Market Cap
$4.19 billion
Optionable
Optionable
Beta
1.09

Social Links















STAA Stock - Frequently Asked Questions

Should I buy or sell STAAR Surgical stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STAA shares.
View STAA analyst ratings
or view top-rated stocks.

What is STAAR Surgical's stock price forecast for 2022?

5 brokers have issued 1 year price objectives for STAAR Surgical's shares. Their STAA share price forecasts range from $87.00 to $98.00. On average, they predict the company's share price to reach $92.00 in the next twelve months. This suggests a possible upside of 4.9% from the stock's current price.
View analysts price targets for STAA
or view top-rated stocks among Wall Street analysts.

How has STAAR Surgical's stock price performed in 2022?

STAAR Surgical's stock was trading at $91.30 at the beginning of 2022. Since then, STAA shares have decreased by 3.9% and is now trading at $87.72.
View the best growth stocks for 2022 here
.

When is STAAR Surgical's next earnings date?

STAAR Surgical is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our STAA earnings forecast
.

How can I listen to STAAR Surgical's earnings call?

STAAR Surgical will be holding an earnings conference call on Wednesday, August 10th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 929-458-6194 with passcode "944172".

How were STAAR Surgical's earnings last quarter?

STAAR Surgical (NASDAQ:STAA) posted its earnings results on Wednesday, November, 3rd. The medical instruments supplier reported $0.12 EPS for the quarter, topping the consensus estimate of $0.11 by $0.01. The medical instruments supplier had revenue of $58.35 million for the quarter, compared to the consensus estimate of $57.70 million. STAAR Surgical had a trailing twelve-month return on equity of 12.78% and a net margin of 11.98%. During the same quarter last year, the business earned $0.14 EPS.

What guidance has STAAR Surgical issued on next quarter's earnings?

STAAR Surgical issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $295.00 million-$295.00 million, compared to the consensus revenue estimate of $295.37 million.

What is Caren Mason's approval rating as STAAR Surgical's CEO?

6 employees have rated STAAR Surgical Chief Executive Officer Caren Mason on Glassdoor.com. Caren Mason has an approval rating of 68% among the company's employees.

What other stocks do shareholders of STAAR Surgical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL), Walt Disney (DIS), CrowdStrike (CRWD), DocuSign (DOCU), Shopify (SHOP), Trade Desk (TTD), Teladoc Health (TDOC) and Roku (ROKU).

What is STAAR Surgical's stock symbol?

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

Who are STAAR Surgical's major shareholders?

STAAR Surgical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (11.05%), Geneva Capital Management LLC (1.90%), Defender Capital LLC. (0.90%), TimesSquare Capital Management LLC (0.84%), Loomis Sayles & Co. L P (0.72%) and Kornitzer Capital Management Inc. KS (0.45%). Insiders that own company stock include Broadwood Partners, LP, Caren L Mason, Deborah J Andrews, Graydon C Hansen, Graydon C Hansen, Hans-Martin Blickensdoerfer, James E Francese, Jon K Hayashida, Keith Holliday, Patrick F Williams, Samuel J Gesten and Scott D Barnes.
View institutional ownership trends
.

How do I buy shares of STAAR Surgical?

Shares of STAA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is STAAR Surgical's stock price today?

One share of STAA stock can currently be purchased for approximately $87.72.

How much money does STAAR Surgical make?

STAAR Surgical (NASDAQ:STAA) has a market capitalization of $4.19 billion and generates $230.47 million in revenue each year. The medical instruments supplier earns $24.50 million in net income (profit) each year or $0.58 on an earnings per share basis.

How many employees does STAAR Surgical have?

STAAR Surgical employs 692 workers across the globe.

Does STAAR Surgical have any subsidiaries?

The following companies are subsidiares of STAAR Surgical: Canon Staar, Frigitronics Inc., STAAR Japan Inc., STAAR Optical Equipment, STAAR Surgical AG, STAAR Surgical PTE. LTD, and Technology (Shanghai) Co. LTD.
Read More

When was STAAR Surgical founded?

STAAR Surgical was founded in 1982.

How can I contact STAAR Surgical?

STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The official website for the company is www.staar.com. The medical instruments supplier can be reached via phone at (626) 303-7902, via email at bmoore@staar.com, or via fax at 626-303-2962.

This page (NASDAQ:STAA) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.